Vascular complications and diabetes: current therapies and future challenges
- PMID: 22272370
- PMCID: PMC3261480
- DOI: 10.1155/2012/209538
Vascular complications and diabetes: current therapies and future challenges
Abstract
Diabetic retinal complications, including macular edema (DME) and proliferative diabetic retinopathy (PDR), are the leading cause of new cases of blindness among adults aged 20-74. Chronic hyperglycemia, considered the underlying cause of diabetic retinopathy, is thought to act first through violation of the pericyte-endothelial coupling. Disruption of microvascular integrity leads to pathologic consequences including hypoxia-induced imbalance in vascular endothelial growth factor (VEGF) signaling. Several anti-VEGF medications are in clinical trials for use in arresting retinal angiogenesis arising from DME and PDR. Although a review of current clinical trials shows promising results, the lack of large prospective studies, head-to-head therapeutic comparisons, and potential long-term and systemic adverse events give cause for optimistic caution. Alternative therapies including targeting pathogenic specific angiogenesis and mural-cell-based therapeutics may offer innovative solutions for currently intractable clinical problems. This paper describes the mechanisms behind diabetic retinal complications, current research supporting anti-VEGF medications, and future therapeutic directions.
Figures

Similar articles
-
Current and Future Pharmacologic Therapies for Diabetic Retinopathy.Curr Pharm Des. 2018;24(41):4903-4910. doi: 10.2174/1381612825666190130140717. Curr Pharm Des. 2018. PMID: 30706803 Review.
-
The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy.Drugs Context. 2018 Aug 13;7:212532. doi: 10.7573/dic.212532. eCollection 2018. Drugs Context. 2018. PMID: 30181760 Free PMC article. Review.
-
Current Treatments and Innovations in Diabetic Retinopathy and Diabetic Macular Edema.Pharmaceutics. 2022 Dec 29;15(1):122. doi: 10.3390/pharmaceutics15010122. Pharmaceutics. 2022. PMID: 36678750 Free PMC article. Review.
-
Diabetic retinopathy and angiogenesis.Curr Diabetes Rev. 2009 Feb;5(1):8-13. doi: 10.2174/157339909787314149. Curr Diabetes Rev. 2009. PMID: 19199892 Review.
-
Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature.Pharmaceutics. 2021 Jul 26;13(8):1137. doi: 10.3390/pharmaceutics13081137. Pharmaceutics. 2021. PMID: 34452097 Free PMC article. Review.
Cited by
-
The effect of Chinese medicine Pu-Ren-Dan on pancreatic angiogenesis in high fat diet/streptozotocin-induced diabetic rats.Indian J Pharmacol. 2013 Nov-Dec;45(6):556-62. doi: 10.4103/0253-7613.121364. Indian J Pharmacol. 2013. PMID: 24347761 Free PMC article.
-
Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models.Front Mol Biosci. 2016 Oct 13;3:67. doi: 10.3389/fmolb.2016.00067. eCollection 2016. Front Mol Biosci. 2016. PMID: 27790618 Free PMC article.
-
Role of matrix metalloproteinase-2 and -9 in the development of diabetic retinopathy.J Ocul Biol Dis Infor. 2012 Jul 6;5(1):1-8. doi: 10.1007/s12177-012-9091-0. Print 2012 Mar. J Ocul Biol Dis Infor. 2012. PMID: 23833698 Free PMC article.
-
Novel Cell-Based and Tissue Engineering Approaches for Induction of Angiogenesis as an Alternative Therapy for Diabetic Retinopathy.Int J Mol Sci. 2020 May 15;21(10):3496. doi: 10.3390/ijms21103496. Int J Mol Sci. 2020. PMID: 32429094 Free PMC article. Review.
-
Angiogenic Factors and Cytokines in Diabetic Retinopathy.J Clin Cell Immunol. 2013;Suppl 1(11):1-12. doi: 10.4172/2155-9899. J Clin Cell Immunol. 2013. PMID: 24319628 Free PMC article.
References
-
- Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. American Journal of Pathology. 2002;160(2):501–509. - PMC - PubMed
-
- Shamoon H, Duffy H, Fleischer N, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine. 1993;329(14):977–986. - PubMed
-
- Turner R. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) The Lancet. 1998;352(9131):837–853. - PubMed
-
- Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053. - PubMed
-
- Crawford TN, Alfaro DV, Kerrison JB, Jablon EP. Diabetic retinopathy and angiogenesis. Current Diabetes Reviews. 2009;5(1):8–13. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources